DC-based vaccines can be engineered to secrete specific cytokines (e.g., IL-12, IFN-γ) that shift ILC function toward an anti-tumor phenotype, promoting ILC1-like activity to enhance cytotoxic T-cell responses [196]. The gene discussed is CCL27; the disease is neoplasm.